After the WHO recommended the use of IL-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra originator Roche pledged not to enforce IP covering the tocilizumab brand in low- and middle-income countries during the pandemic. But humanitarian organization MSF says this does not go far enough.
In the wake of a World Health Organization recommendation to use interleukin-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra (tocilizumab) originator Roche has pledged not to enforce intellectual property covering the brand in low- and middle-income countries during the pandemic.
However, humanitarian organization Médecins Sans Frontières has complained that this move does not go far enough, calling for the brand...
In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.
The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.
Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
